zwitterionic oral selective Nav1.7 inh. for pain

predicted QD dosing, completed Ph. I, discont.

PK optimization of prior scaffold

J. Med. Chem., Mar. 8, 2021

Genentech, South San Francisco, CA / Xenon

The Genentech Nav1.7 inhibitor (GDC-0310) is a oral Ph. I clinical candidate for pain. Nav1.7 has been a hot target for pain, and we previously highlighted a Nav1.7 inhibitor…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks